In ovarian cancer, RIG-I activation leads to an upregulation of MHC class I and to a secretion of proinflammatory mediators leading to the hypothesis that this could increase antitumor activity within microenvironment (Kübler et al. 2010). Here, RIGI is linked to ovarian cancer.